Valiant Co

Valiant Co Long-term Debt

The Long-Term Debt of Valiant Co (002643.SZ) as of Nov 19, 2026 is 1.27 B CNY. In the previous year, Long-Term Debt was 1.35 B CNY — a change of -5.74% (lower).

Long-term Debt

1.27 BCNY

YoY

-5.74%

Last updated:

Long-Term Debt of Valiant Co is 2025 1.27 B CNY. Long-Term Debt of Valiant Co was 2024 1.35 B CNY. It decreases by -5.74% lower compared to the previous year.

The Valiant Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
6.13 M CNY
Jan 1, 2019
4.23 M CNY
Jan 1, 2020
110.72 M CNY
Jan 1, 2021
337.58 M CNY
Jan 1, 2022
345.24 M CNY
Jan 1, 2023
1.00 B CNY
Jan 1, 2024
1.35 B CNY
Jan 1, 2025
1.27 B CNY
The Valiant Co Long-term Debt history
YEARLong-term DebtYoY
1.27 BCNY-5.74%
1.35 BCNY+34.63%
1.00 BCNY+190.81%
345.24 MCNY+2.27%
337.58 MCNY+204.90%
110.72 MCNY+2,518.22%
4.23 MCNY-30.98%
6.13 MCNY-22.08%
7.86 MCNY-19.76%
9.80 MCNY-2.00%
10.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Co Stock analysis

What does Valiant Co do? Valiant Co., Ltd. generates revenue through three core business segments. The Information Materials Industry segment produces and sells display materials and functional materials, targeting customers in the electronics and manufacturing sectors. The Environmental Protection Materials Industry segment develops and manufactures new zeolite environmental protection materials for tail gas purification, serving automotive and industrial clients requiring emission control solutions. The Large Health Industry segment focuses on pharmaceutical production, life sciences, and in vitro diagnostic services, catering to healthcare providers and medical facilities. The company's products include display materials, functional materials, new zeolite environmental protection materials, pharmaceuticals, and in vitro diagnostic services. These offerings are sold across the three industry segments, with the Environmental Protection Materials segment specifically addressing tail gas purification needs. The Large Health Industry segment's in vitro diagnostic services support healthcare operations through specialized medical solutions. Valiant Co., Ltd. serves diverse customer segments including electronics manufacturers, automotive industries, industrial emission control clients, and healthcare providers. The firm's revenue streams are derived from the sale of physical products like display materials and zeolite materials, as well as service-based offerings in diagnostics and pharmaceuticals. The company's business model relies on manufacturing and selling these products across its three operational segments. Valiant Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Co stock

Long-Term Debt of Valiant Co is 1.27 B CNY in 2025.

Long-Term Debt of Valiant Co changed from 1.35 B CNY to 1.27 B CNY, representing a -5.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Valiant Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Valiant Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Valiant Co

All Key Metrics — Valiant Co